Table 1.
Odds ratios for HNSCC associated with HPV 16 L1 seropositivity in case-control studies
| Seroprevalence % | ||||||
|---|---|---|---|---|---|---|
| Author | Period of enrollment | Location | Tumor site | Cases (N) | Controls (N) | Adj OR (95% CI) |
| Schwartz | 1990–1995 | US | Oral cavity | 51.4 (259) | 35.0 (446) | 2.3 (1.6–3.3)1 |
| Oropharynx | ||||||
| Herrero | 1996–1999 | International | Oral cavity | 8.9 (1,319) | 6.0 (1,527) | 1.5 (1.1–2.1)2 |
| Oropharynx | 13.4 (238) | 6.0 (1,527) | 3.5 (2.1–5.9)2 | |||
| Smith | 2000–2004 | US | Oral cavity | 26.8 (142) | 22.4 (326) | 1.2 (0.7–2.0)3 |
| Oropharynx | 50.0 (62) | 22.4 (326) | 3.5 (1.9–6.5)3 | |||
| Furniss | 1999–2003 | US | Oral cavity | 14.7 (190) | 10.7 (550) | 1.4 (0.9–2.4)4 |
| Tongue, tonsil, pharynx | 40.3 (228) | 10.7 (550) | 6.0 (4.1–8.7) | |||
| Pintos | 1997–2001 | Canada | Oral cavity | 6.9 (72) | 3.9 (129) | 3.9 (0.9–17.5)5 |
| Base of tongue and tonsil | 12.5 (72) | 3.9 (129) | 182.3 (7–4,753)5 | |||
| Sitas | 1995–2000 | South Africa | Oral cavity and pharynx | 36.3 (102) | 30.8 (2,055) | 1.5 (0.89–2.51)6 |
| Oropharynx | 13.4 (238) | 6.0 (1,527) | 3.5 (2.1–5.9)6 | |||
| D'souza | 2000–2005 | US | Oropharynx | 57.0 (100) | 7.0 (200) | 32.2 (14.6–71.3)7 |
| All | ||||||
| Gillison | 2000–2006 | US | HPV16-positive tumor | 59 (92) | 9 (184) | 18.3 (6.8–49)8 |
| HPV16-negative tumor | 8 (148) | 8 (296) | 0.9 (0.4–2.2)8 | |||
1
Adjusted for age, gender, smoking, alcohol
2
Adjusted for age, gender, country, smoking, alcohol, paan chewing
3
Adjusted for age, alcohol, tobacco
4
Adjusted for age, race, gender, smoking, drinking
5
Adjusted for age, gender, tobacco, alcohol
6
Adjusted for age, gender, education, residence, alcohol, tobacco
7
Adjusted for age, gender, tobacco, alcohol, oral hygiene, family history of HNSCC
8
Adjusted for race, tobacco, alcohol, marijuana, dental hygiene, number of oral sex partners. Matched on age and gender